View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Heidi Mo Jinghui ... (+2)
  • Heidi Mo Jinghui
  • John Cheong Ming Chern

Nanofilm Technologies International Ltd - 1H25: Revenue In Line But Ea...

Nanofilm’s 1H25 revenue of S$107m (+30% yoy) met our expectation, forming 46% of our full-year estimate. However, earnings remain soft, at only S$1.6m or 12% of our full-year estimate (vs S$3.7m loss in 1H24) due to a softer gross margin. Revenue growth was driven by the AMBU and IEBU segments. Nanofilm expects consistent growth in 2025. Although Nanofilm’s revenue is healthy, it may take time to achieve meaningful earnings. Maintain SELL with a 22% higher target price of S$0.56.

Adrian Loh Tzum Yung ... (+6)
  • Adrian Loh Tzum Yung
  • Heidi Mo Jinghui
  • John Cheong Ming Chern
  • Jonathan Koh
  • Lester Siew
  • Roy Chen Chengzhi

Singapore Daily: Friday, August 15, 2025

KEY HIGHLIGHTS Results AEM Holdings (AEM SP/SELL/S$1.51/Target:S$1.25): 1H25: Revenue in line but earnings miss expectations; maintain SELL. CapitaLand Investment (CLI SP/BUY/S$2.72/Target: S$3.49): 1H25: Strategic recycling and lodging expansion support growth outlook. Maintain BUY. ComfortDelGro Corporation (CD SP/BUY/S$1.53/Target: S$1.70): 2Q25: A steady ride with decent yield and earnings growth. First Resources (FR SP/BUY/S$1.68//Target: S$1.85): 1H25: Results above expectations thank...

 PRESS RELEASE

RUBIS: Information relating to the total number of voting rights and s...

RUBIS: Information relating to the total number of voting rights and shares as of 31/07/2025 Paris, 11 August 2025, 5:45 pm INFORMATION ON TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES PURSUANT TO ARTICLE L.233-8 II OF THE FRENCH COMMERCIAL CODE AND ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY Date Class of shares Number of shares Number of theoretical voting rights Number of exercisable voting rights (excluding shares bought back by the Company (deprived of voting rights) and shares deprived of voting rights in accordance with art. L. 233-14...

 PRESS RELEASE

RUBIS: Déclaration de capital et de droits de vote au 31/07/2025

RUBIS: Déclaration de capital et de droits de vote au 31/07/2025 Paris, le 11 août 2025, 17h45 INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS PRÉVUES PAR L’ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L’ARTICLE 223-16 DU RÈGLEMENT GÉNÉRAL DE L’AUTORITÉ DES MARCHÉS FINANCIERS Date Catégorie d’actions Nombre d’actions Nombre de droits de vote théoriques Nombre de droits de vote exerçables(hors actions autodétenues (privées du droit de vote) et actions privées du droit de vote conformément à l’article L. 233-14 du Code de commerce) 31 juillet 2025 Actions ordinai...

Damien Choplain ... (+3)
  • Damien Choplain
  • Maria Vara
  • Oscar Haffen Lamm

End of coverage

From 5th August 2025, we will no longer include the following companies in our coverage:EVOTECMEDIOSDBV Technologies

 PRESS RELEASE

Information regarding the total number of voting rights and total numb...

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)   Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights    07/31/2025      136,975,159     Total gross of voting rights: 136,975,159 Total net* of voting rights: 136,810,568 * Net t...

 PRESS RELEASE

Information relative au nombre total des droits de vote et d’actions ...

Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025 Information relative au nombre total des droits de vote etd’actions composant le capital social au 31 juillet 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 Date Nombre totald’actionscomposant le capital social Nombre total de droits de vote     31/07/2025       136.975.159   Total brut des droits de vote : ...

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
Oscar Haffen Lamm
  • Oscar Haffen Lamm

Medincell: Uzedy outperformed in Q2; Olanzapine LAI still on track for...

Yesterday Teva reported Q2 2025 results, highlighted by a re-acceleration in Uzedy sales to USD54m (+24% vs css), with Teva raising the product's sales guidance to USD190-200m for FY25 from USD160m. TRx data continues to support the product's growth (3x TRx YoY), with Teva reporting >80% NBRx fr

Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
 PRESS RELEASE

DBV Technologies announces filing of 2025 Half-Year Report ― Condition...

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need (the “Company”), today announced the filing, for the semester ended June 30, 2025, of its Half-Y...

 PRESS RELEASE

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modali...

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique au stade clinique (la « Société »), a annoncé aujourd'hui que son Rapport Financier Semestriel 2025 (le « RFS ») a été déposé auprès de l’Autorité des Marchés Financiers (« AMF ») en France. Le RFS au 30 juin 2025 peut êtr...

 PRESS RELEASE

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial R...

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported financial results for the Second Quarter of 2025. The quarterly and half-year financial statements were approved by the Board of Directors on July 29, 2025. Financial Highlights for the Second Quarter Ended June 30, 2025The Company’s interim con...

 PRESS RELEASE

DBV Technologies publie ses résultats financiers du 2ème trimestre et ...

DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société biopharmaceutique au stade clinique, publie aujourd'hui ses résultats financiers du deuxième trimestre 2025. Les états financiers trimestriels et semestriels ont été approuvés par le Conseil d'Administration le 29 juillet 2025. Résultats financiers pour le semestre c...

 PRESS RELEASE

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO ...

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF Regulated InformationChâtillon, France, July 28, 2025 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2025: 210,069 DBV Technologies shares,€ 171,30...

 PRESS RELEASE

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BH...

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations RéglementéesChâtillon, France, le 28 juillet (22 h 30 CET) 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), laboratoire biopharmaceutique français, publie aujourd’hui le bilan semestriel de son contrat de liquidité avec ODDO BHF. Au titre du contrat de liquidité confié à ODDO BHF, portant sur les actions de la société DBV TECHNOLOGIES, à la date du 30 juin 2025, les moyens suivants figuraient au compte de...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch